

Joint Section on Tumors Newsletter



The American Association of Neurological Surgeons
Congress of Neurological Surgeons



Joseph Piepmeier, MD, Editor

Fall 1996

JOINT SECTION ON TUMORS OFFICERS

CHAIRMAN

William F. Chandler, MD

PAST-CHAIRMAN

Peter McL. Black, MD, PhD

SECRETARY-TREASURER

Mark Bernstein, MD, FRCS(C)

ADVISORY BOARD

Patrick J. Kelly, MD
Paul L. Kornblith, MD
Edward R. Laws, Jr., MD
Robert A. Morantz, MD
Robert G. Ojemann, MD
Charles B. Wilson, MD
Harold F. Young, MD

COMMITTEE CHAIRMEN

Awards

Michael Apuzzo, MD
Edward R. Laws, Jr., MD, FACS

Bylaws

Michael D. Walker, MD

International

Nicholas de Tribolet, MD
Armando Basso, MD
Andrew Kaye, MD
Kintomo Takakura, MD
David G. T. Thomas, MD, FRCP, FRCS

Membership

Timothy B. Mapstone, MD

Membership Services

Mark Bernstein, MD, FRCS(C)

Newsletter

Joseph Piepmeier, MD

Nominating

Dennis E. Bullard, MD

Pediatrics

Lie Sutton, MD

Program

Ossama Al-Mefty, MD, FACS
Richard Ellenbogen, MD
Joseph Piepmeier, MD
Laligam N. Sekhar, MD

Research

Corey Raffel, MD
John Walsh, MD

Resources

Eben Alexander, III, MD

Spine Liaison

Arnold H. Menezes, MD

Task Force

Mark L. Rosenblum, MD

CHAIRMAN'S ADDRESS

by

William F. Chandler, M.D.

The Joint Section was very pleased to present the first grant award for support of neuro-oncology research. A grant of \$15,000 was made possible through the generosity of the National Brain Tumor Foundation. This funding was awarded to Jeffrey Bruce from Columbia University. The award was presented to Dr. Bruce at a plenary session at the recent AANS Annual Meeting in Minneapolis. This will be an annual event at the AANS meeting. Applications for the 1997 award will be available later this year.

The second Neuro-oncology Satellite Symposium will be held in conjunction with the CNS Annual Meeting in Montreal. It will begin at 1 PM on Thursday, October 3rd and will end at 5 PM on Friday, October 4th. Ray Sawaya has put together a diversified and stimulating scientific program. There will be a number of outstanding invited speakers addressing topics of epidemiology, radiobiology, regulation of cell growth, molecular therapy and prognosis. In addition, there will be a number of papers presented in open scientific sessions and posters available for review and discussion during an informal dinner on Thursday evening. Please plan to attend and to encourage your colleagues and collaborators in other fields to join you. Registration will be available along with your general CNS meeting registration or separately during the CNS meeting.

Bill Couldwell has organized an excellent program for the Wednesday afternoon Joint Section session at the upcoming CNS Annual Meeting. The topic will be "Medical and Surgical Management of Pituitary Tumors." The invited speakers will include Ed Laws, Ed Oldfield, and Rudy Fahlbusch. In addition to this program, the Preuss Resident, Mahaley Clinical, and Young Investigator Award papers will be presented, along with several other selected papers.

We continue to look for new individuals to become involved in the Joint Section. I would encourage you to contact me if you have a particular interest or new ideas.

IN THIS ISSUE

Chairman's Address	1
Secretary's Report	2
Mahaley Award	3
Preuss Award	3
Committee Reports	4
Young Investigator's Award.....	5
News Items	6
Membership Application	Insert

**Minutes of the Joint Section on Tumors
Executive Council Meeting
April 26, 1996
Minneapolis, Minnesota**

The Executive Council of the Joint Section on Tumors was called to order at 1:35 p.m. by Chairman Bill Chandler. Also present were Mark Bernstein, Mitch Berger, Keith Black, Peter Black, Bill Couldwell, Roberta Glick, Ed Laws, Kevin Lillehei, Andrew Kaye, Paul Kornblith, Tim Mapstone, Jack Rock, Mark Rosenblum, Jim Rutka, Ray Sawaya, and David Thomas.

Minutes:

The minutes of the Executive Council Meeting held at the CNS Meeting in San Francisco, California were accepted as written.

Treasurer's Report:

The financial report was given by Dr. Bernstein. The Section continues to be in stable financial condition with total assets of \$141,546.00 as of December 31, 1995. The net revenue for 1995 was \$34,140.00. The proposed budget for 1996 was briefly discussed vis a vis significant revenues and expenses anticipated associated with the Satellite Symposium at the CNS Meeting in Montreal in October.

Awards Committee:

The Award recipients were reviewed. The winner of the Mahaley Award is Dr. William Hitzelberger, who will be introduced by Dr. Bernstein. The winner of the Preuss Award is Dr. Margaret Wallenfriedman, who will be introduced by Dr. Laws. The Young Investigator Award goes to Dr. Liliana Goumnerova, who will be introduced by Dr. Chandler. The NBTF Research Grant was won by Dr. Jeffrey Bruce out of about 20 applications; he will be introduced by Dr. Berger. The Farber Award was awarded to Dr. Greg Cairncross and Dr. Peter Black will introduce him. It was also decided that if

continued efforts to obtain reimbursement from the Preuss Foundation prove futile, the name of this Award will be changed to The Joint Tumor Section Resident Research Award.

Bylaws Committee:

Dr. Rock reported that he examined the last revision of the Bylaws in March 1994 and has not identified any Bylaws presently requiring revision.

Education:

Dr. Alexander could not attend, but he had submitted a letter outlining his efforts to develop a CD ROM devoted to the brain tumor research literature. If any members have any suggestions in this area, they are invited to send them to Dr. Alexander.

International Committee:

Mr. Thomas reminded the group of the European Congress of Neuro-oncology October 6-9, 1996 in Wurzburg, Germany. He also reiterated that the 12th International Congress on Brain Tumor Research and Therapy will be held in Oxford, England September 20-23, 1997 which is just before the CNS Meeting that year in New Orleans.

Membership Committee:

Dr. Lillehei presented the list of four new Active Members, one new International Member, and one International Member who resigned. Currently, we have 505 Active Members, 51 International, 7 Resident, 14 Associate/retired, 3 Honorary, and 57 Adjunct. He spoke to the problem of poor representation from residents and has composed a letter that will be sent to all Neurosurgery Residency Program Chairmen encouraging them to inform their residents of the excellent opportunities associated with membership in the Joint Section on Tumors. Various

other ideas were suggested such as starting a "mentorship" program in which residents interested in neuro-oncology might be connected to an accomplished member of the Section. We also discussed the possibility of a special forum for residents at the Satellite Symposia and agreed that residents should definitely be offered a discount on the registration for such Symposia.

Membership Services:

Dr. Rutka has produced a list of benefits of membership in the Joint Section. Members are asked to think of further potential benefits we can generate to make membership in our Section more attractive to prospective members.

Newsletter:

Dr. Piepmeier could not attend, but he was thanked for the excellent job he is doing on the Newsletter.

Nominating Committee:

No business is identified at the present but there will be some business at the next Meeting as new Officers will be elected in the Spring of 1997.

Program Committee:

Dr. Mapstone spoke briefly to the Joint Tumor Section Session at this Meeting on Wednesday on the topic of Pediatric Brain Tumors. Dr. Couldwell outlined the Session at the CNS Meeting in Montreal in October 1996 on Pituitary Tumors. Dr. Berger will be responsible for the Session at the AANS Meeting in April 1997, and Dr. Keith Black for the Session at the CNS Meeting in 1997.

Research Committee:

Dr. Glick prepared a detailed research report outlining the poor success rate

(cont on page 8)

MAHALEY CLINICAL RESEARCH AWARD PAPER

High Levels of Speech Recognition With Multichannel Electrical Stimulation of the Human Auditory Brainstem

*William E. Hitzelberger, Derald Brackmann,
Steve Otto, Robert V. Shannon*



William E. Hitzelberger presents the Mahaley Clinical Research Award paper.

High levels of speech recognition have recently been observed in a patient with neurofibromatosis 2 (NF 2) treated with a multichannel auditory brainstem implant (ABI). The ABI is designed to be placed in the lateral recess of the fourth ventricle during translabyrinthine surgery to remove a vestibular schwannoma in patients with NF2. The present ABI contains 8 active electrodes intended to stimulate the cochlear nucleus (CN) complex. Although the 8 electrodes are not aligned with a tonotopic axis in the CN, most patients receive different pitch perceptions associated with stimulation of individual electrodes. One patient, who perceives a large pitch range across her electrodes, is able to recognize 60% of the words in simple sentences using only the sound through her ABI. She can converse in a limited manner over the telephone. This case provides the proof-by-existence that electrical stimulation of selective neural populations at the level of the CN can produce patterns of auditory information to the brain that are sufficient for word recognition.

Of a total of 17 patients with the multichannel ABI, 8 receive some (10% to 20% correct) recognition of words in sentences with only the sound from the implant, and all 16 stimulatable patients receive useful sound sensations that improve their ability to communicate when combined with lipreading.

PREUSS RESIDENT'S RESEARCH AWARD PAPER

Antisense Oligonucleotides to Insulin-Like Growth Factor 1 Receptor Mediates Systemic Defense Against C6 Rat Glioma Tumor

*Margaret A. Wallenfriedman, John A. Conrad,
Lan Chiang, Eric P. Flores, Dennis Y.K. Wen*



The winner of the Preuss Research Award, Margaret A. Wallenfriedman, was introduced by Edward R. Laws, Jr.

Previous studies of antisense oligonucleotides (AONs) to insulin-like growth factor-1 (IGF-1) or its receptor (IGF-1R) have employed viral vectors to transfect tumor cells. These transfected cells, in turn, are capable of activating the immune system of immunocompetent syngeneic rodents to recognize both transfected and nontransfected tumor cells. As a consequence, animals immunized in this manner exhibit complete tumor regression and prolonged survival when challenged with either peripherally or centrally implanted brain tumor cells.

In the present study, we have examined the effects of directly administering antisense to IGF-1R *in vivo* or *ex vivo* on C6 tumor growth in BDIX rats without the use of a viral vector. AONs administered in this fashion have recently been shown to be transported into the cytoplasm and nucleus of cells to suppress gene expression and protein synthesis by blocking the translation of its complementary mRNA. We engineered an IGF-1R AON of 21 nucleotides in length, and a randomized nonsense oligonucleotide (NON) identical in length and nucleotide composition to the IGF-1R AON as a control. In their *in vivo* study, C6 peripheral gliomas were established in the flank of 9 BDIX rats. Ten days after tumor implantation, the animals

(con't on page 7)

JOINT SECTION COMMITTEE REPORTS

Education Committee Report by Eben Alexander III, MD

The initial goal is to make a CD ROM that could be used by neurosurgical and neuro-oncological investigators interested in the basic clinical and scientific literature concerning brain tumors. Ideally, entire articles, including all of the graphics, images and charts, would be included on the CD ROM ("the Brain Tumor Literature CD") in a very accessible format. In addition, hypertext links between references would allow for one to easily move around the article (i.e., from text to linked graphics), from one article to another, and possibly to specific places in other articles. All this would be combined with an easy navigation system that would keep a map of one's progress and allow one to easily back track and take other avenues. I think that this kind of knowledge structure with all of the important articles in their entirety easily cross-linked with hypertext would be a very valuable learning tool. It might set an example that could be utilized not only by neurosurgeons interested in brain tumors, but also be extended to other medical fields as well as other scientific interests in general.

Research Committee Report by Roberta Glick

The Research Committee of the Joint Section of Tumors has taken on the following tasks for the year 1996-1997:

1. To keep members informed of news regarding Federal research funding for NIH and cancer research.
2. To alert members of specific Neuro-oncology research grant opportunities.
3. To conduct a survey of the research opportunities available to residents in their residency training program (Drs. Raffel and Warnick will be mailing these soon).
4. To compile an updated list of all available clinical protocols, including gene therapy, for brain tumor patients.

We anticipate that this information will soon be available on line as well.

First, the news from Washington, D.C. NCI Director Richard Klausner, M.D. has recently asked Congress to give the NCI an added \$269.5 million in fiscal year 1988 to fund "extraordinary opportunities for new investments" in the battle against cancer. The five stated goals for such "Investment Opportunities" are:

1. Cancer genetics: to identify every gene predisposing to cancer.
2. Preclinical models of cancer.
3. Detection technologies, including imaging diagnosis.
4. Developmental diagnostics: tests that allow treatment based on properties of the tumor cell.
5. Investigator initiated research: increase grants funded by 30%.

We will look forward to hearing more about this in the future.

Also new from NCI: if at first you don't succeed in winning an investigator-initiated RO1 grant, the NCI will give you a chance to try again in a more accelerated manner. Under an experimental program, grants within ten points of the payline will be eligible for the Accelerated Executive Review Program. In the first round of such appeals, 13 grant applications went before the committee and eight won funding. Good Luck!

For those applying for FIRST and Career Awards from NIH, a new "just in time" streamlined application procedure that omits the detailed budget and other form items and makes the application process a bit more tolerable is now in place.

Other good news: NIH Director Harold Varmus has announced plans to disband the Recombinant DNA Advisory Committee (RAC) and the FDA will handle all new gene therapy proposals. This will enable investigators to obtain approval for gene therapy in half the time.

Below is a list of funding sources relevant to neuro-oncology research. Some of these were previously described in the Newsletter and so we have included only the phone numbers to which inquiries can be made.

1. US Dept. Health and Human Services- Public Health Service: NIH- NINDS (301-496-9248)
2. American Cancer Society (404-329-7612)
3. AANS: Young Investigator Award (708-692-9500)
4. Cancer Research Foundation of America (703-836-4412)
5. National Science Foundation (703-306-1130)
6. Fogarty International Center (301-496-1653)
7. Sloan Basic Research Fellowships (for Neuroscience Research) (212-649-1649)
8. American Institute for Cancer Research (202-328-7744)
9. Small Business Innovative Research (SBIR)- NIH

The last source on the list is a new way to fund research by collaborating with a corporate entity (e.g., gene company) and forming a small business endeavor. Funding is at the 75% level.

The Research Committee is interested in input from the Section members. Please feel free to forward your suggestions and ideas to Roberta P. Glick at 312-633-6328 (Phone) or 312-633-6494 (FAX).

Membership Committee Report by Kevin O. Lillehei, MD

The current membership of the Joint Section on Tumors has risen to 504 Active members, 52 International Members, 7 residents, 14 Associate/Retired, 3 Honorary, and 57 Adjunct members.

YOUNG INVESTIGATOR AWARD

Expression of Neurotrophin Receptors in Medulloblastoma and the Developing Cerebellum

*Liliana Goumnerova, Scott L. Pomeroy,
Lyuda Goritchenko, Rosalind A. Segal*



William Chandler and Naomi Berkowitz present the Young Investigator Award to Liliana Goumnerova.

Medulloblastoma is the most common malignant brain tumor of childhood. It arises in the posterior fossa, is composed of small round cells with the ability to differentiate along both glial and neuronal lines, and is thought to derive from the external granule cell layer of the developing cerebellum. We have shown that medulloblastoma tumor samples express mRNA for the neurotrophin receptors *trkB* and *trkC*. By Kaplan-Meier analysis, patients with tumors expressing high levels of *trkC* mRNA had significantly longer intervals without disease progression.

We have subsequently analyzed tissue from medulloblastoma and cerebellum by immunohistochemistry and in situ hybridization for expression of mRNA and receptor proteins. Tumor samples were sectioned and mounted on slides in preparation for immunohistochemistry. Antibodies specific for *trkB* and *trkC* were obtained, characterized and used for staining tissue samples from medulloblastoma and sections from infant brain. The pattern of tissue staining and receptor expression in the developing human cerebellum will be presented. Sections from the same patient were also mounted on slides in preparation for in situ hybridization, which was performed in tandem with the immunohistochemistry. The probes utilized were against the extracellular domains of the receptor proteins *trkB* and *trkC*; in situ hybridization were correlated with those from the immunohistochemistry both for the normal tissues and for the medulloblastoma samples on a cellular level.

These data will be presented and we will show the normal distribution pattern of neurotrophin receptors in the human brain and the expression of these receptors in medulloblastoma samples on a cellular level.

AANS/CNS JOINT SECTION ON TUMORS
October 2, 1996

AWARD PRESENTATIONS

Preuss Resident's Research Award

“NF2 Gene Transcript Mutations in
Spinal Ependymomas”
Barry D. Birch, MD

Mahaley Clinical Research Award

“Solitary Brain Metastases: Surgery, Stereotactic
Radiosurgery and/or Radiation Therapy”
Walter Hall, MD

Young Investigator Award

“High-Flow Microinfusion of c-myc Antisense
Oligonucleotides Prolongs Survival in an Animal
Model of Intracranial Malignant Glioma”
William Broaddus, MD

SCIENTIFIC PROGRAM

MEDICAL AND SURGICAL MANAGEMENT OF PITUITARY TUMORS

Moderators: William Couldwell and William Chandler

Learning Objective: After attending this seminar, the participant will have an improved understanding of the medical and surgical management of pituitary tumors. The participant will be able to describe the management of recurrent adenoma, acromegaly, and Cushing's disease and will also be able to explain avenues for future therapy of pituitary tumors. The participant also will have an increased understanding of the current research that is ongoing in the field of neuro-oncology.

- | | |
|-------------|--|
| 2:30-2:50PM | The Recurrent Adenoma
Edward R. Laws, Jr. |
| 2:50-3:10PM | Contemporary Surgical Management of Cushing's Disease
Edward Oldfield |
| 3:10-3:30PM | Avenues for Future Therapy
Rudolph Fahlbusch |
| 3:30-4:00PM | COFFEE BREAK/EXHIBITS |
| 4:00-5:30PM | OPEN SCIENTIFIC SESSION
Moderators: Mark Bernstein and Mark Rosenblum |

NEWS ITEMS

Tumor Satellite Symposium October 3-4, 1996 Montreal, Quebec, Canada

The Second Tumor Satellite Symposium of the Joint Section on Tumors is scheduled to take place in conjunction with the Congress of Neurological Surgeons' Meeting in Montreal, Canada on October 3rd and 4th, 1996. The conference chairmen are Drs. Bill Chandler and Peter Black, and the scientific program chairman is Dr. Raymond Sawaya.

Four general topics will be covered. These include: epidemiology, radiobiology, cell cycle control, and molecular therapy. In addition, there will be three open scientific sessions, during which competitively selected abstracts will be presented.

The design of this symposium was developed with input from Dr. Mitch Berger, who successfully managed the first tumor symposium. A strong participation by the neurosurgical community was evident and resulted in the exposure of advanced research in brain tumors. A similar experience is anticipated this time, and in addition, extra efforts are being made to encourage the participation of all related disciplines.

For any questions concerning this program, please contact Dr. Raymond Sawaya at phone: (713) 792-2400; FAX: (713) 794-4950. e-mail: raymond_sawaya@qksurg.mda.uth.edu.

National Brain Tumor Foundation Supports Neuro-oncology Award

Jeffrey Bruce, MD, of Columbia University is this year's recipient of the National Brain Tumor Foundation's Neuro-oncology Award. This prestigious \$15,000 award was given to Dr. Bruce for his research on "Novel Intratumoral Drug Delivery System for Treatment of Brain Tumors in a Rat Glioma Model."

.....

National Brain Tumor Foundation Patient and Health Professional Conference in Southern California

The National Brain Tumor Foundation and the San Diego Gamma Knife Center/Scripps Hospital are the co-sponsors of a one-day conference for brain tumor patients and their families on November 16, 1996 in La Jolla, CA. This exciting Southern California conference will feature leading healthcare professionals and workshops focusing on the latest in treatments, coping, and caregiving. For more information please call the National Brain Tumor Foundation at 1-800-934-CURE.

Young Investigator Award

William Chandler, MD, Chairman of the AANS/CNS Joint Section on Tumors, presented the Spring 1996 Young Investigator Award, funded by the American Brain Tumor Association, to Liliانا Goumnerova, MD. Dr. Goumnerova of The Children's Hospital in Boston was recognized for her outstanding research on the role of neurotrophins in both cerebellar development and medulloblastoma.

The Fall 1996 Young Investigator Award will be presented at the CNS Meeting in Montreal.

American Brain Tumor Association 1996-1998 Research Fellowships

The American Brain Tumor Association proudly announces the recipients of its coveted Research Fellowship Awards for 1996-1998. Based upon the advice of ABTA'S distinguished Scientific Advisory Council, these \$50,000 fellowships have been awarded to:

Fellow: Robert Friedlander, MD
Sponsor: Junying Yuan, PHD
Institution: Massachusetts General Hospital, Boston

Fellow: Linda Liau, MD
Sponsor: Keith Black, MD
Institution: University of California, Los Angeles
Research: Cytokine Gene Transfer for Immunotherapy of Malignant Gliomas

Fellow: Tobey MacDonald, MD
Sponsor: Walter Laug, MD
Institution: Children's Hospital, Los Angeles
Research: Relation of Proteases and Their Inhibitors to Brain Tumor Invasion and Migration

Fellow: James Markert, MD
Sponsor: Richard Whitley, MD
Institution: University of Alabama at Birmingham
Research: Mutant Herpes Simplex Virus as a Vector for Cytokine Gene Therapy of Glioma

Fellow: James Olson, MD, PHD
Sponsor: Stephen Tapscott, MD, PHD
Institution: Fred Hutchinson Cancer Research Center, Seattle
Research: Identification of Neural Differentiation Defects in Medulloblastoma

Fellow: John Park, MD, PHD
Sponsor: Charles Stiles, PHD
Institution: Dana Farber Cancer Institute, Boston
Research: Role of PDGF Autocrine Loops in the Pathogenesis of Malignant Astrocytomas

(cont' on page 8)

ANNOUNCEMENT

**SUMMER INTERNSHIP ON THE
EPIDEMIOLOGY OF BRAIN TUMORS**

**FUNDED BY THE
CENTRAL BRAIN TUMOR REGISTRY OF THE U.S.**

OBJECTIVE: To further research on the epidemiology of brain tumors.

BUDGET: \$5,000.00.

SCOPE OF WORK: Epidemiologic proposals involving a focused analysis of existing data or pilot projects to test new hypotheses are eligible for funding under the direction of a senior investigator. Projects must be based in the U.S.

ELIGIBILITY: Any student currently enrolled in a graduate level degree program in epidemiology at a U.S. accredited institution.

APPLICATION: The required application form must be completed in full and be accompanied by the student's curriculum vitae and research proposal and the sponsor's name, letter of support and curriculum vitae.

Applications may be obtained by calling the CBTRUS office at (312) 579-0021.

SPONSOR: This epidemiologic work must be conducted under the direction of a sponsoring epidemiologist or neuroscience researcher. Preference will be given to students working with senior investigators who have publications and grants in brain tumor research.

DEADLINE: **Applications must be received by January 15, 1997.**
Send applications to: The Central Brain Tumor Registry of the U.S.
3333 West 47th Street. Chicago, IL 60632

AWARD PERIOD: June 1 through August 30, 1997, or to coincide with summer internship schedule at particular institution at which research is to be conducted.

FINAL REPORT: **October 1, 1997.**

Preuss Award (con't from page 3)

were randomly assigned to receive either intratumoral injections of IGF-1RAON (n=5) or intratumoral injections of NON (n=4) injections of AON and NON were given at a concentration of 100 μ M in a 50 μ l volume on Days 11, 13, and 15 after tumor implantation.

Average tumor volumes over Days 11 to 25 showed that the IGF-1RAON-treated rats had significantly reduced tumor volumes compared to NON controls (ANOVA, $p < 0.05$). Prior to treatment, tumor volumes for AON and NON animals were 1529 ± 229 and 1775 ± 319 cu mm (mean \pm SEM), respectively. At 4 days after the last injection, tumor volume in IGF-1RAON-treated animals was reduced to 66% of their size before treatment. In contrast, tumors in NON-treated animals increased to 150%. In the *ex vivo* study, 9 BDIX rats with established peripheral C6 gliomas in the right flank were treated with a single dose of 10×10^5 irradiated C6 cells which were preincubated in either IGF-1RAON or NON and injected into the contralateral tumor-free flank. Prior to treatment, tumor sizes in the AON- and NON-treated animals were 2425 ± 727 and 2090 ± 575 cu mm, respectively. One week after treatment, tumors in AON-immunized animals decreased to 67% of their pre-treatment size while tumors in NON-treated animals increased to 130%. A single treatment with IGF-1RAON preincubated cells, therefore, yielded a significantly reduced tumor burden compared to NON-treated controls (ANOVA, $p < 0.05$).

These data suggest that direct injections of IGF-1RAON or the injection of tumor cells modified *ex vivo* with IGF-1RAON may be clinically useful as either a vaccine or an immunological therapy for CNS glioma without the use of viral vectors for transfection.

Minutes (con't from page 2)

on new RO1 grant applications (13.1%) and the fact that hospital funding for research will decrease as federal funding of hospitals decreases. Fortunately, the NIH is enjoying a projected 5.7% increase in its budget. She suggested compiling available research funding agencies and an updated list of brain tumor clinical protocols and listing both of these on the Internet. The issue of research opportunities for residents was also discussed and it was noted that Drs. Warnick and Raffel are sending a questionnaire to all residents to try to get a handle on the magnitude of the challenge.

Task Forces:

1. Guidelines

Dr. Rock reported on a meeting in Chicago that he recently attended representing the Joint Section on Tumors, where it was indicated that each Section will really be responsible for generating and pursuing topics for guideline development. He updated the group on the progress with the low-grade glioma guidelines on which he and Dr. Bernstein have been working on behalf of the Joint Tumor Section. At a meeting held the day before, chaired by Ed Shaw, the first draft of the guidelines on low-grade glioma was discussed. It was concluded, based on a critical literature review, that there existed only treatment options: to biopsy or not, to resect or not, and to radiate or not were all acceptable options for a patient who has an imaging diagnosis of a low-grade glioma and is neurologically intact, with seizures only. The next draft will be available probably by the end of June and will be circulated to the Membership of the Executive Council for approval before joint publication in the neurosurgery, neurology, and radiation oncology literature. At this point, Dr. Florin joined the meeting and apprised the

group of the new structure of the Assessment Committee which is an "umbrella" for three other committees: the Outcomes Committee chaired by Dr. R. Toselli, the Guidelines Committee chaired by Dr. B. Walters, and the Devices, Drugs, and Procedures Committee chaired by Dr. A. Friedman. Dr. Florin exhorted the Section to be proactive in outcomes and guidelines development.

2. Multi-disciplinary Neuro-oncology Effort

Dr. Rosenblum gave an update. Dr. Chandler has corresponded with the various subspecialty societies and has been given the names of representatives by all groups except ASTRO. It was suggested that representatives from all constituent groups get together for a meeting sometime within the next year. There will be a meeting of the Joint Tumor Section officers, Dr. Rosenblum, and Dr. Cairncross the next day to further discuss this initiative.

CNS Satellite Symposium:

Dr. Sawaya updated the group on plans for the Satellite Symposium to be held immediately following the CNS Meeting in Montreal in October, 1996. A planning meeting of the organizing committee had been held the day before. The topics of discussion are Epidemiology and Prognosis, Radiobiology, Regulation of Cell Growth, and Molecular Therapy. Dr. Sawaya has secured all but one invited speaker and has allotted time for 21 platform papers to be selected from submitted abstracts. The abstract form will be sent out and the proceedings will be published in the Journal of Neuro-Oncology. Dr. Sawaya was thanked for his excellent efforts.

AACR Satellite Symposium:

Dr. Peter Black spoke of the first ever Brain Tumor Satellite Symposium in conjunction with the AACR to be held June 7-9, 1997. The AACR will be responsible for most of the financial

arrangements, but the scientific program committee will consist of Drs. Black, Chandler, Piepmeyer, and Rosenblum from the Joint Tumor Section.

Journal of Neuro-Oncology:

The Journal has agreed to publish in an upcoming issue an advertisement describing the Mission Statement and benefits to members of the Joint Section on Tumors.

Central Brain Tumor Registry:

Dr. Berger has communicated to Ms. Kruchko that Joint Tumor Section members would be interested in accessing the CBTR's database and contributing in a more formal way to the collection and management of the data obtained by the CBTR.

The Meeting was adjourned at 2:55 p.m.

Respectfully submitted,

Mark Bernstein MD, FRCSC
Secretary-Treasurer
Joint Section on Tumors, AANS and
CNS

Fellowships (con't from page 6)

Fellow: David Raben, MD
Sponsor: David Curiel, MD
Institution: University of Alabama at
Birmingham
Research: Genetic Radio-Isotope
Targeting Strategies for Brain Tumors

Fellowship applications for July, 1997
may be obtained from the ABATA
office:

Phone: 847-827-9910

Fax: 847-827-9918

E-mail: ABATA@aol.com

The deadline for completed applications is January 6, 1997.

APPLICATION FOR MEMBERSHIP

Joint Section on Tumors of

The American Association of Neurological Surgeons and Congress of Neurological Surgeons



Name: _____

Home Address: _____

Home Phone Number: _____

Business Address: _____

Business Phone Number: _____

Fax Number: _____

I wish to apply for:

Active Membership International Membership Resident Membership

*If applying for Resident Membership, please have chairman forward confirmation of your resident status.

Program: _____

Chairman: _____

Year of anticipated completion: _____

Are you a Member of:

The American Association of Neurological Surgeons? Yes No

Active Active (Foreign) Active (Provisional) Associate

Candidate Corresponding Honorary Lifetime

Congress of Neurological Surgeons? Yes No

Active Honorary International Resident Senior

(continued on reverse side)



Please list any membership in other Neurosurgical Societies: _____

Other Societies: _____

Are you currently involved in Active Brain Tumor Research?

Clinical: Yes No

Basic: Yes No

Special areas of interest: _____

Suggestions on Section activities that would be of benefit to you: _____

Please send your complete application and curriculum vitae to:

Kevin O. Lillehei, MD
University of Colorado Health Center
4200 East 9th Avenue
Campus #C-307
Denver, CO 80262



TUMOR SATELLITE SYMPOSIUM
OCTOBER 3-4, 1996

THURSDAY, OCTOBER 3, 1996

EPIDEMIOLOGY & PROGNOSIS

Moderators: Raymond Sawaya, MD & William Chandler, MD

- 1:00 - 3:00 p.m. Welcome: William Chandler, MD
- 1:05 - 1:15 p.m. Introduction: Raymond Sawaya, MD
- 1:15 - 1:45 p.m. Susan Preston-Martin, PhD
- 1:45 - 2:10 p.m. Stuart Grossman, MD
- 2:10 - 2:35 p.m. Douglas Arnold, MD
- 2:35 - 3:00 p.m. Janet M. Bruner, MD
- 3:00 - 3:30 p.m. BREAK
- Moderators: Peter Black, MD & James Rutka, MD
- 3:30 - 6:00 p.m. Free Papers Session
- 6:30 - 8:30 p.m. Dinner with Poster Review

FRIDAY, OCTOBER 4, 1996

RADIOBIOLOGY

- 7:00 - 7:30 a.m. Continental Breakfast
- 7:30 - 4:30 p.m. Poster Review
- Moderators: Mark Bernstein, MD & Mitch Berger, MD
- 7:30 - 7:45 a.m. Introduction: Mark Bernstein, MD
- 7:45 - 8:15 a.m. Kie-Kian Ang, MD, PhD
- 8:15 - 8:45 a.m. Jay Loeffler, MD
- 8:45 - 10:00 a.m. Free Papers Session
- 10:00-10:30 a.m. BREAK

REGULATION OF CELL GROWTH

- Moderators: Victor Levin, MD & Timothy Mapstone, MD
- 10:30 - 11:00 a.m. Albert Won, MD
- 11:00 - 11:30 a.m. David Malkin, MD
- 11:30 - 12:00 p.m. David Beach, PhD
- 12:00 - 1:00 p.m. LUNCH

MOLECULAR THERAPY

- Moderators: Henry Brem, MD & Walter Hall, MD
- 1:00 - 1:15 p.m. Introduction: Al Yung, MD
- 1:15 - 1:40 p.m. Dao Nguyen, MD
- 1:40 - 2:05 p.m. Leaf Huang, PhD
- 2:05 - 2:30 p.m. Edward H. Oldfield, MD
- 2:30 - 3:00 p.m. BREAK
- Moderators: Joseph Piepmeier, MD & Ronald Warnick, MD
- 3:00 - 4:30 p.m. Free Papers Session

ADJOURN

UPCOMING MEETINGS

European Congress of Neuro-oncology
October 6-9, 1996

Wurzburg, Germany

Contact: The Congress Secretariat

IMEDEX, Bruistensingel 360, P.O. Box 3283,
5203 DG's-Hertogenbosch, The Netherlands,
Phone +31-73.6.42.92.85, Fax +31-73.6.41.47.66

News items may be mailed to:
Joseph M. Piepmeier, MD
Yale University School of Medicine
Section of Neurological Surgery
P. O. Box 208039
New Haven, CT 06520-8039
(203)785-6916 fax

Joseph Piepmeier, MD, thanks Susan Christopher, RN, BSN, for her administrative assistance and B. Lee Ligon, PhD, for editing and formatting the *Newsletter*.

**Joint Section on Tumors
of the AANS/CNS
22 South Washington Street
Park Ridge, Illinois 60068-4287**

FIRST CLASS
U.S. POSTAGE
PAID
DesPlaines, IL
Permit No. 329